Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.

Autor:	Zeven K; Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium., Lauwers Y; Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium., De Mey L; Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., Debacker JM; Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium.; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium., De Pauw T; Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium., De Groof TWM; Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium., Devoogdt N; Molecular Imaging and Therapy Research Group, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Jazyk:	angličtina
Zdroj:	Immunotherapy advances [Immunother Adv] 2024 Aug 26; Vol. 4 (1), pp. ltae006. Date of Electronic Publication: 2024 Aug 26 (Print Publication: 2024).
DOI:	10.1093/immadv/ltae006
Abstrakt:	The evolving landscape of cancer immunotherapy has revolutionized cancer treatment. However, the dynamic tumor microenvironment has led to variable clinical outcomes, indicating a need for predictive biomarkers. Noninvasive nuclear imaging, using radiolabeled modalities, has aided in patient selection and monitoring of their treatment response. This approach holds promise for improving diagnostic accuracy, providing a more personalized treatment regimen, and enhancing the clinical response. Nanobodies or single-domain antibodies, derived from camelid heavy-chain antibodies, allow early timepoint detection of targets with high target-to-background ratios. To date, a plethora of nanobodies have been developed for nuclear imaging of tumor-specific antigens, immune checkpoints, and immune cells, both at a preclinical and clinical level. This review comprehensively outlines the recent advancements in nanobody-based nuclear imaging, both on preclinical and clinical levels. Additionally, the impact and expected future advancements on the use of nanobody-based radiopharmaceuticals in supporting cancer diagnosis and treatment follow-up are discussed. Competing Interests: Nick Devoogdt is co-founder of the companies Precirix and Abscint. (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu